Literature DB >> 6615687

Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine.

W G Rapeport, G T McInnes, G G Thompson, G Forrest, B K Park, M J Brodie.   

Abstract

Antipyrine metabolism, daily urinary 6-beta-hydroxycortisol excretion, carbamazepine (CBZ) half-lives and leucocyte delta-aminolaevulinic acid synthase (ALA.S) activities were measured following 2 weeks' treatment with CBZ 400 mg and 600 mg once daily in eight healthy male volunteers. Dose-dependent induction of antipyrine metabolism was demonstrated but cortisol hydroxylation appeared maximally induced by the 400 mg dose. CBZ half-lives fell significantly in both studies (P less than 0.01 in each case) but a greater fall was seen with the higher dose (P less than 0.01). Plasma CBZ concentrations were higher following the eighth doses (P less than 0.01) in both studies. Leucocyte ALA.S activity increased by a mean of 657% following 1 week's treatment with 400 mg CBZ and 1145% on the 600 mg dose. In both studies ALA.S activities fell towards baseline during the second week of treatment. CBZ possesses potent dose-dependent hetero- and auto-inducing properties. Leucocyte ALA.S activity may represent a novel in vivo index of extrahepatic enzyme induction in man.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6615687      PMCID: PMC1427988          DOI: 10.1111/j.1365-2125.1983.tb04976.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  [THE BIOCHEMICAL INTERPRETATION OF HYPNOTIC ADDICTION].

Authors:  K SCHMID; F CORNU; P IMHOF; H KEBERLE
Journal:  Schweiz Med Wochenschr       Date:  1964-02-15

2.  Hereditary coproporphyria. Demonstration of the abnormalities in haem biosynthesis in peripheral blood.

Authors:  M J Brodie; G G Thompson; M R Moore; A D Beattie; A Goldberg
Journal:  Q J Med       Date:  1977-04

3.  Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin.

Authors:  E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

Review 4.  Clinical implications of enzyme induction and enzyme inhibition.

Authors:  B K Park; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

5.  Effect of low-dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects.

Authors:  E Perucca; M Ruprah; A Richens; B K Park; D J Betteridge; A M Hedges
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

6.  Multicompartmental analysis of serum, urine and bile concentrations of rifampicin and desacetyl-rifampicin in subjects treated for one week.

Authors:  G Acocella; R Mattiussi; G Segre
Journal:  Pharmacol Res Commun       Date:  1978-03

Review 7.  Assessment of urinary 6 beta-hydroxycortisol as an in vivo index of mixed-function oxygenase activity.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

8.  High-pressure liquid chromatographic analysis of antipyrine in small plasma samples.

Authors:  L Shargel; W M Cheung; A B Yu
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

9.  Induction of delta-aminolaevulinic acid synthase in leucocytes of patients on phenytoin therapy--comparison with changes in rat hepatic tissue.

Authors:  K E McColl; M R Moore; G G Thompson; A Goldberg
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

10.  Pharmacokinetics of Carbamazepine in man: a review.

Authors:  S Pynnönen
Journal:  Ther Drug Monit       Date:  1979       Impact factor: 3.681

View more
  20 in total

Review 1.  Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.

Authors:  Stig Thunell; Erik Pomp; Atle Brun
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

2.  Early stage autoinduction of carbamazepine metabolism in humans.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

3.  Changes in circulating thyroid hormones during short-term hepatic enzyme induction with carbamazepine.

Authors:  J M Connell; W G Rapeport; S Gordon; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Effect of stanozolol on delta-aminolaevulinic acid synthase and hepatic monooxygenase activity in man and rat.

Authors:  G G Thompson; M Small; G D Lowe; C D Forbes; B K Park; G Scobie; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Rapid tolerance to acute psychomotor impairment with carbamazepine in epileptic patients.

Authors:  J G Larkin; P J McKee; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

Review 6.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

7.  The effects of chronic carbamazepine treatment of haem biosynthesis in man and rat.

Authors:  G M McGuire; G J Macphee; G G Thompson; B K Park; M R Moore; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy.

Authors:  P N Patsalos; J S Duncan; S D Shorvon
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

Review 9.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

10.  Changes in circulating androgens during short term carbamazepine therapy.

Authors:  J M Connell; W G Rapeport; G H Beastall; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.